Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 259 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Insulin Clear all
Completed Phase 4 Interventional Results available

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406
View directory record Official record
Conditions
Stable Angina, Metabolic Syndrome
Interventions
Ranolazine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional

Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition

NCT07265323
View directory record Official record
Conditions
Alzheimer s Disease, Alzheimer Blood Biomarkers, Insulin Sensitivity
Interventions
Physiological Insulin Intervention
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Withdrawn Phase 4 Interventional

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir/grazoprevir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 4 Interventional

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

NCT00207402
View directory record Official record
Conditions
Hepatitis C
Interventions
rosiglitazone
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Phase 4 Interventional

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598
View directory record Official record
Conditions
HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of L-citrulline Supplementation on Vascular Function in Metabolic Syndrome

NCT06025357
View directory record Official record
Conditions
Metabolic Syndrome, Menopause
Interventions
L-Citrulline supplementation, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
45 Years to 79 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery

NCT00694473
View directory record Official record
Conditions
Critical Illness
Interventions
Freestyle Navigator
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

GIP: Glucose-dependent Insulinotropic Peptide

NCT00239707
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
GIP, Modified GIP, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Sep 4, 2026, 1:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Fenugreek on Blood Sugar and Insulin in Diabetic Humans

NCT00597350
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Trigonella foenum-graecum (fenugreek)
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 4, 2026, 1:48 PM EDT
Withdrawn Phase 4 Interventional

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

NCT00906529
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Levemir (Detemir) and Novolog (Aspart) Insulin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Monitoring Postprandial Blood Glucose and Insulin in Fruit Snacks

NCT06458946
View directory record Official record
Conditions
Blood Glucose, Blood Insulin
Interventions
Fruit snack 1, Fruit snack 2, Fruit snack 3, Fruit snack 4, Fruit snack 5, Confection control
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Postprandial Response to Fruit Juice

NCT07103083
View directory record Official record
Conditions
Blood Glucose, Blood Insulin
Interventions
Beverage 1, Beverage 2, Beverage 3, Beverage 4, Beverage 5, Beverage 6
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IR and Microvascular Blood Flow in SCI

NCT02034331
View directory record Official record
Conditions
Spinal Cord Injury, Insulin Resistance
Interventions
Insulin iontophoresis, Placebo Iontophoresis, Acetylcholine Iontophoresis, Heat application
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

NCT06340854
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Fresno, California • Hawthorne, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance

NCT00264251
View directory record Official record
Conditions
HIV Infections, Insulin Resistance, Obesity
Interventions
Weight loss through diet and exercise, Rosiglitazone insulin sensitizing agent
Behavioral · Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
20 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2007 · Synced Sep 4, 2026, 1:48 PM EDT
Completed No phase listed Observational

Novel Therapy for Glucose Intolerance in HIV Disease

NCT02006914
View directory record Official record
Conditions
Insulin Resistance
Interventions
Chromium Picolinate
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 4, 2026, 1:48 PM EDT
Withdrawn Phase 2 Interventional

A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.

NCT01067118
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
LINjeta U-100 Insulin, Humalog U-100
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Stanford, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 4, 2026, 1:48 PM EDT
Terminated Not applicable Interventional Results available

2-5 Intermittent Caloric Restriction in HIV

NCT03489109
View directory record Official record
Conditions
Human Immunodeficiency Virus, Metabolic Syndrome
Interventions
Intermittent fasting, Standard of Care
Behavioral · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

NCT00667732
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 4, 2026, 1:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Increased, Egg-Based Protein Intake on Muscle Composition,

NCT01396915
View directory record Official record
Conditions
Muscle Composition, Sarcopenia, Hypertrophy, Inflammation
Interventions
Dietary Protein Intake
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
55 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

NCT00346697
View directory record Official record
Conditions
HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
Interventions
Omega-3 fatty acid administration, Placebo
Drug
Lead sponsor
Brown, Todd, M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 4, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

NCT00913497
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
insulin glulisine, insulin aspart
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
4 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 4, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 4, 2026, 1:48 PM EDT
Recruiting Phase 2Phase 3 Interventional

Exercise and Intranasal Insulin in Type 2 Diabetes

NCT07675499
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 4, 2026, 1:48 PM EDT